Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy. 記事全文>>> Novo Nordisk’s New Obesity Drug Beats Wegovy Weight Loss in Early Trial ...

Danish drugmaker Novo Nordisk said on Friday a phase 2 trial for its big hope in tackling obesity, an improved GLP-1 drug called semaglutide, showed a weight loss of up to 13.8 percent in people ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ... Novo Nordisk ousts CEO after falling behind in weight loss market.